연구성과로 돌아가기

2025 연구성과별 연구자 정보 (326 / 1187)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke San An, Chun San An, C 32 GNT Pharm Co Ltd, Yongin, South Korea jinsoo22@gmail.com;
Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke Gwag, Byoung Joo Gwag, BJ 33 GNT Pharm Co Ltd, Yongin, South Korea jinsoo22@gmail.com;
Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke Choi, Dennis W. Choi, DW 34 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol, Seoul, South Korea jinsoo22@gmail.com;
Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke Choi, Dennis W. Choi, DW 34 Stony Brook Univ, Sch Med, Dept Neurol, Stony Brook, NY, USA jinsoo22@gmail.com;
Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke Hong, Ji Man Hong, JM 35 Ajou Univ, Med Ctr, Sch Med, Dept Neurol, 164 Worldcup Ro, Suwon 16499, South Korea AAE-2686-2022 Hong, Ji Man jinsoo22@gmail.com;
Early Administration of Nelonemdaz May Improve the Stroke Outcomes in Patients With Acute Stroke Kwon, Sun U. Kwon, SU 36 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Neurol, Seoul, South Korea jinsoo22@gmail.com;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Lim, Young-Suk Lim, YS 1 교신저자 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol,Asan Liver Ctr, Seoul, South Korea AFQ-5165-2022 Lim, Young-Suk limys@amc.seoul.kr;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Yu, Ming-Lung Yu, ML 2 Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan AAZ-4306-2020 Yu, Ming-Lung 0000-0001-8145-1900 Yu, Ming-Lung limys@amc.seoul.kr;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Choi, Jonggi Choi, J 3 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol,Asan Liver Ctr, Seoul, South Korea L-1521-2019 Choi, Jonggi limys@amc.seoul.kr;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Chen, Chi-Yi Chen, CY 4 Chia Yi Christian Hosp, Ditmanson Med Fdn, Chiayi, Taiwan limys@amc.seoul.kr;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Choi, Won-Mook Choi, WM 5 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol,Asan Liver Ctr, Seoul, South Korea limys@amc.seoul.kr;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Kang, Wonseok Kang, W 6 Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea limys@amc.seoul.kr;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Kim, Gi-Ae Kim, GA 7 Kyung Hee Univ, Kyung Hee Univ Hosp, Seoul, South Korea AAZ-2547-2021 Kim, Gi-Ae limys@amc.seoul.kr;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Kim, Hyung Joon Kim, HJ 8 Chung Ang Univ, Chung Ang Univ Hosp, Seoul, South Korea limys@amc.seoul.kr;
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION) interim results from a randomised controlled trial Bin Lee, Yun Bin Lee, Y 9 Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea limys@amc.seoul.kr;
페이지 이동: